- Home
- INM vs TNFA Comparison
INM vs TNFA Comparison
Compare INM & TNFA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INM
- TNFA
- Stock Information
- Founded
- INM 1981
- TNFA 2014
- Country
- INM Canada
- TNFA United States
- Employees
- INM N/A
- TNFA N/A
- Industry
- INM Biotechnology: Pharmaceutical Preparations
- TNFA
- Sector
- INM Health Care
- TNFA
- Exchange
- INM Nasdaq
- TNFA NYSE
- Market Cap
- INM 3.4M
- TNFA 3.2M
- IPO Year
- INM N/A
- TNFA N/A
- Fundamental
- Price
- INM $4.95
- TNFA $1.16
- Analyst Decision
- INM
- TNFA
- Analyst Count
- INM 0
- TNFA 0
- Target Price
- INM N/A
- TNFA N/A
- AVG Volume (30 Days)
- INM 26.6K
- TNFA 297.1K
- Earning Date
- INM 02-11-2025
- TNFA 11-14-2024
- Dividend Yield
- INM N/A
- TNFA N/A
- EPS Growth
- INM N/A
- TNFA N/A
- EPS
- INM N/A
- TNFA N/A
- Revenue
- INM $4,960,506.00
- TNFA N/A
- Revenue This Year
- INM N/A
- TNFA N/A
- Revenue Next Year
- INM N/A
- TNFA N/A
- P/E Ratio
- INM N/A
- TNFA N/A
- Revenue Growth
- INM 5.17
- TNFA N/A
- 52 Week Low
- INM $2.42
- TNFA $1.05
- 52 Week High
- INM $15.70
- TNFA $5.91
- Technical
- Relative Strength Index (RSI)
- INM 55.90
- TNFA 44.65
- Support Level
- INM $4.07
- TNFA $1.12
- Resistance Level
- INM $5.41
- TNFA $1.52
- Average True Range (ATR)
- INM 0.39
- TNFA 0.12
- MACD
- INM 0.01
- TNFA -0.00
- Stochastic Oscillator
- INM 67.83
- TNFA 12.20
About INM InMed Pharmaceuticals Inc.
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease, INM-089's pharmacological and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.
About TNFA TNF PHARMACEUTICALS INC EFFEC
TNF Pharmaceuticals Inc is a clinical-stage pharmaceutical company committed to extending a healthy lifespan. The company is developing and commercializing two therapeutic platforms. MyMD-1 is a small molecule that regulates the immunometabolic system to treat autoimmune diseases, including multiple sclerosis, diabetes, rheumatoid arthritis, and inflammatory bowel disease. It is being developed to treat age-related illnesses such as frailty and sarcopenia. Supera-CBD is a synthetic derivative of CBD being developed to treat various conditions, including epilepsy, pain, and anxiety/depression, through its effects on the CB2 receptor, opioid receptors, and monoamine oxidase enzyme type B.